Rofecoxib exerts no effect on platelet plug formation in healthy volunteers.

摘要: Objective. Although rofecoxib has very high selectivity for cyclo-oxygenase 2 (COX-2), supratherapeutic concentrations (> 1000 mg) inhibit purified human COX-1 in vitro and TXB formation vivo. It is therefore possible that higher doses of may affect platelet function. This could be important if given to thrombocytopenic patients. In these cases, already moderate inhibition function precipitate bleeding complications. We set out investigate the influence on healthy volunteers. Methods. up a balanced-randomised, double-blind, placebo-controlled, two way cross-over study. Peripheral blood was withdrawn from 42 volunteers before 3 hours after intake 50, 250, 500 mg or placebo (n=14 per group). Platelet assessed by analyzer (PFA-100) which measures collagen-epinephrine induced closure time (CEPI-CT) under shear stress. Results. CEPI-CT increased 14% (p = 0.002) 11% 0.003) three at dosages mg, respectively. The increase versus baseline not significantly different period compared with active treatment periods (n 42, p > 0.05). Conclusions. Rofecoxib does impair Thus, appears valuable analgetic antipyretic agent therapy patients risk bleeding.